Franklin Resources Inc Rigel Pharmaceuticals Inc Transaction History

Franklin Resources Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$1.07 - $1.39 $118,363 - $153,761	-110,620 Reduced 61.22%	70,063 $75,000
Q2 2023 Aug 11, 2023	BUY	$1.12 - $1.82 $138,583 - $225,197	123,735 Added 217.28%	180,683 $233,000
Q1 2023 May 12, 2023	SELL	$1.25 - $2.0 $4,737 - $7,580	-3,790 Reduced 6.24%	56,948 $75,000
Q4 2022 Feb 10, 2023	BUY	$0.67 - $11.9 $1,134 - $20,146	1,693 Added 2.87%	60,738 $91,000
Q3 2022 Nov 14, 2022	BUY	$1.1 - $12.2 $587 - $6,514	534 Added 0.91%	59,045 $69,000
Q2 2022 Aug 11, 2022	SELL	$0.67 - $3.19 $18,318 - $87,217	-27,341 Reduced 31.85%	58,511 $66,000
Q1 2022 May 13, 2022	BUY	$2.22 - $3.45 $9,317 - $14,479	4,197 Added 5.14%	85,852 $257,000
Q4 2021 Feb 11, 2022	BUY	$2.36 - $3.57 $159,715 - $241,603	67,676 Added 484.13%	81,655 $216,000
Q3 2021 Nov 12, 2021	BUY	$3.5 - $4.5 $5,250 - $6,750	1,500 Added 12.02%	13,979 $50,000
Q2 2021 Aug 13, 2021	BUY	$3.09 - $4.54 $38,560 - $56,654	12,479 New	12,479 $54,000

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $3.53B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

Stay updated on Franklin Resources Inc with notifications on news.